MX2020001319A - Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica. - Google Patents

Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica.

Info

Publication number
MX2020001319A
MX2020001319A MX2020001319A MX2020001319A MX2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A MX 2020001319 A MX2020001319 A MX 2020001319A
Authority
MX
Mexico
Prior art keywords
tympanic membrane
modulation
growth factor
sustained release
epidermal growth
Prior art date
Application number
MX2020001319A
Other languages
English (en)
Inventor
Luke Santa Maria Peter
Peter Yang Yunzhi
Kim Sungwoo
DOMVILLE - LEWIS Chloe
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2020001319A publication Critical patent/MX2020001319A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A61F11/20—Ear surgery
    • A61F11/202—Surgical middle-ear ventilation or drainage, e.g. permanent; Implants therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/18—Internal ear or nose parts, e.g. ear-drums
    • A61F2002/183—Ear parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Composite Materials (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan composiciones y métodos para la generación o el tratamiento de perforaciones crónicas en la membrana timpánica mediante la modulación de la actividad del HB-EGF; en los métodos de la invención, una membrana timpánica perforada crónicamente se pone en contacto tópicamente con una dosis eficaz de factor de crecimiento epidérmico de unión a la heparina, HB-EGF, o un agente que tiene actividad de HB-EGF, durante un período suficiente para proporcionar una curación mejorada de la perforación de la membrana; en algunas modalidades la dosis de HB-EGF se proporciona en una formulación de liberación sostenida; en otras modalidades se proporciona la administración regular de una formulación de liberación no sostenida; en algunas modalidades, una formulación de liberación sostenida es biodegradable; en otras modalidades la liberación sostenida está provista por un dispositivo, por ejemplo una bomba u otro dispositivo de liberación.
MX2020001319A 2013-05-15 2015-11-13 Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica. MX2020001319A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361823749P 2013-05-15 2013-05-15

Publications (1)

Publication Number Publication Date
MX2020001319A true MX2020001319A (es) 2020-03-20

Family

ID=51898980

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015015774A MX2015015774A (es) 2013-05-15 2014-04-09 Modulación de la actividad del factor de crecimiento epidérmico de unión a la heparina para curar la membrana timpánica.
MX2020001319A MX2020001319A (es) 2013-05-15 2015-11-13 Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015015774A MX2015015774A (es) 2013-05-15 2014-04-09 Modulación de la actividad del factor de crecimiento epidérmico de unión a la heparina para curar la membrana timpánica.

Country Status (27)

Country Link
US (3) US20160074476A1 (es)
EP (2) EP3708181A1 (es)
JP (1) JP6316943B2 (es)
KR (1) KR102318748B1 (es)
CN (2) CN113559242A (es)
AU (2) AU2014265901B2 (es)
BR (2) BR112015028367B1 (es)
CA (1) CA2912411C (es)
CY (1) CY1123464T1 (es)
DK (1) DK2996709T3 (es)
ES (1) ES2805002T3 (es)
HK (1) HK1217166A1 (es)
HR (1) HRP20200971T1 (es)
HU (1) HUE049294T2 (es)
IL (2) IL242454B (es)
LT (1) LT2996709T (es)
MX (2) MX2015015774A (es)
PH (2) PH12015502577B1 (es)
PL (1) PL2996709T3 (es)
PT (1) PT2996709T (es)
RS (1) RS60412B1 (es)
RU (2) RU2018146249A (es)
SG (1) SG11201509347UA (es)
SI (1) SI2996709T1 (es)
UA (1) UA120037C2 (es)
WO (1) WO2014186075A2 (es)
ZA (1) ZA201508289B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102634748B1 (ko) 2018-06-15 2024-02-13 삼성전자주식회사 포토 마스크용 펠리클 및 이의 제조 방법
EP4008353A4 (en) * 2019-07-31 2023-05-10 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR OTIC ADMINISTRATION
WO2022065404A1 (ja) * 2020-09-25 2022-03-31 アステラス製薬株式会社 耳内投与用の医薬組成物
US11984398B2 (en) 2021-03-08 2024-05-14 Changxin Memory Technologies, Inc. Semiconductor structure and manufacturing method thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
CA2121129A1 (en) 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US6514533B1 (en) * 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
CA2251129A1 (en) 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
WO1999017820A1 (en) 1997-10-03 1999-04-15 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
US6191109B1 (en) * 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
MXPA00010110A (es) * 1998-04-17 2002-08-06 Angiogenix Inc Factores angiogenicos terapeuticos y metodos para su uso.
CA2395902A1 (en) 1999-12-28 2001-07-05 Asger Lau Dalmose Dual chamber syringe with a dual function piston
US20030229113A1 (en) 2000-03-24 2003-12-11 Koji Hashimoto Keratinocyte growth inhibitors and hydroxamic acid derivatives
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20090148486A1 (en) * 2005-04-28 2009-06-11 Helen Lu Compositions and methods for treating pulp inflammations caused by infection or trauma
KR20080026198A (ko) * 2005-06-30 2008-03-24 안트로제네시스 코포레이션 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
WO2007037514A1 (ja) 2005-09-28 2007-04-05 Kagoshima University ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
US8093213B2 (en) 2007-04-30 2012-01-10 Nationwide Children's Hospital, Inc. Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
US20090192079A1 (en) * 2007-10-09 2009-07-30 Genzyme Corporation Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen
WO2009093970A1 (en) * 2008-01-22 2009-07-30 Omnio Healer Ab Method of improving wound healing
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
RU2544367C2 (ru) * 2008-06-26 2015-03-20 НОБЕЛЬФАРМА Ко., ЛТД Средство для восстановления барабанной перепонки или наружного слухового прохода
CN102574917A (zh) * 2009-08-17 2012-07-11 株式会社未来创药研究所 含有抗hb-egf抗体作为有效成分的药物组合物
WO2011103382A2 (en) * 2010-02-22 2011-08-25 The Brigham And Women's Hospital Compositions and methods for inducing angiogenesis
US8556854B2 (en) 2010-07-22 2013-10-15 Becton, Dickinson And Company Dual chamber syringe with retractable needle
EP2731549B1 (en) * 2011-07-11 2021-09-15 Ear Science Institute Australia Device for ear drum repair
US9821118B2 (en) 2011-09-02 2017-11-21 Unl Holdings Llc Automatic reconstitution for dual chamber syringe
DK2844309T3 (da) * 2012-06-28 2022-01-24 The Administrators Of The Tulane Educational Fund Selektivt polymeriserbare sammensætninger
EP2983723A4 (en) * 2013-04-09 2016-12-14 Univ Leland Stanford Junior CHITOSAN-LACTIDE HYDROGELS RETICULATED

Also Published As

Publication number Publication date
EP3708181A1 (en) 2020-09-16
LT2996709T (lt) 2020-08-10
PH12020551126A1 (en) 2021-12-13
EP2996709B1 (en) 2020-05-06
AU2019200630A1 (en) 2019-02-21
PH12015502577A1 (en) 2016-02-29
AU2014265901A1 (en) 2015-11-26
EP2996709A2 (en) 2016-03-23
UA120037C2 (uk) 2019-09-25
HK1217166A1 (zh) 2016-12-30
CY1123464T1 (el) 2022-03-24
RU2676483C2 (ru) 2018-12-29
RU2015148636A (ru) 2017-06-20
PH12015502577B1 (en) 2016-02-29
BR122020011229B1 (pt) 2022-06-07
BR112015028367A2 (pt) 2017-07-25
SI2996709T1 (sl) 2020-09-30
PL2996709T3 (pl) 2021-02-08
IL273329B (en) 2021-05-31
US11963998B2 (en) 2024-04-23
BR112015028367B1 (pt) 2020-12-01
RS60412B1 (sr) 2020-07-31
MX2015015774A (es) 2016-07-26
WO2014186075A2 (en) 2014-11-20
HUE049294T2 (hu) 2020-09-28
WO2014186075A3 (en) 2015-06-04
JP2016520080A (ja) 2016-07-11
US20220111006A1 (en) 2022-04-14
CA2912411C (en) 2022-10-25
IL273329A (en) 2020-04-30
AU2019200630B2 (en) 2020-08-27
ES2805002T3 (es) 2021-02-10
CN113559242A (zh) 2021-10-29
HRP20200971T1 (hr) 2020-10-02
AU2014265901B2 (en) 2018-11-08
IL242454B (en) 2020-05-31
DK2996709T3 (da) 2020-06-02
ZA201508289B (en) 2019-02-27
KR102318748B1 (ko) 2021-10-27
CN105555296A (zh) 2016-05-04
EP2996709A4 (en) 2016-11-16
CA2912411A1 (en) 2014-11-20
US20180256684A1 (en) 2018-09-13
RU2018146249A (ru) 2019-01-18
KR20160013063A (ko) 2016-02-03
US20160074476A1 (en) 2016-03-17
SG11201509347UA (en) 2015-12-30
US11235027B2 (en) 2022-02-01
JP6316943B2 (ja) 2018-04-25
PT2996709T (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
PH12015500115A1 (en) Glucagon analogues
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
UA111148C2 (uk) Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю
PH12015502577A1 (en) Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
FI20115135A0 (fi) Mikrofibrilloidun selluloosan tulehduksia estävä vaikutus
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
ITMI20120370A1 (it) Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico.
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
CY1122538T1 (el) Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση
EA201690445A1 (ru) Лечение рака
CY1118633T1 (el) Χρηση pidotimod για την θεραπευτικη αγωγη ατοπικης δερματιτιδας
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
EA201492173A1 (ru) Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе